WO2023128636A1 - Composition contenant un extrait de racine de bruyère pour le soulagement, la prévention ou le traitement de l'obésité et de maladies métaboliques - Google Patents

Composition contenant un extrait de racine de bruyère pour le soulagement, la prévention ou le traitement de l'obésité et de maladies métaboliques Download PDF

Info

Publication number
WO2023128636A1
WO2023128636A1 PCT/KR2022/021566 KR2022021566W WO2023128636A1 WO 2023128636 A1 WO2023128636 A1 WO 2023128636A1 KR 2022021566 W KR2022021566 W KR 2022021566W WO 2023128636 A1 WO2023128636 A1 WO 2023128636A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
group
obesity
control group
disease
Prior art date
Application number
PCT/KR2022/021566
Other languages
English (en)
Korean (ko)
Inventor
강종수
박일범
박현제
차주영
송애리
황윤경
Original Assignee
주식회사 유한건강생활
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220187409A external-priority patent/KR20230101740A/ko
Application filed by 주식회사 유한건강생활 filed Critical 주식회사 유한건강생활
Publication of WO2023128636A1 publication Critical patent/WO2023128636A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)

Definitions

  • the present invention relates to a composition for the improvement, prevention or treatment of metabolic diseases, comprising an extract of the root of Blackbrier as an active ingredient.
  • Cardiovascular diseases such as heart attack, hypertension, arteriosclerosis, and stroke account for 30% of all mortality worldwide.
  • obesity, diabetes, hypertension, arteriosclerosis, heart disease, stroke, etc. are understood as a single syndrome having a common etiology, insulin resistance due to increased body fat, although they appear to be different diseases.
  • Obesity is one of the most common nutritional disorders worldwide, and according to WHO statistics, currently about 250 million people are classified as obese patients, and it is predicted that about 300 million people will suffer from obesity in 20 years.
  • the obesity refers to a state in which excessive body fat is accumulated due to an imbalance in calorie metabolism due to excessive energy intake or decreased energy consumption. am.
  • obesity is defined as a case of 25 or more when measuring BMI (body mass index). It is a measure of obesity.
  • obesity causes abnormal development of normal adipocytes, in which preadipocytes differentiate into adipocytes. Hyperdifferentiation into adipocytes and accumulation of fat in adipocytes increase the number and size of adipocytes, resulting in more severe obesity symptoms. It is known that When pre-adipocytes reach confluence, the cell cycle is stopped, cell proliferation is stopped, and hormones such as 3-isobutyl-1-methyl-xanthine (IBMX), dexamethasone (DEX), and insulin differentiate into fat cells (adipogenisis). is induced, and obesity is caused by hypertrophy and hyperplasia of fat cells in tissues.
  • IBMX 3-isobutyl-1-methyl-xanthine
  • DEX dexamethasone
  • insulin differentiate into fat cells adipogenisis
  • SREBP-1c sterol regulatory element binding proteins-1c
  • PPAR- ⁇ peroxisome proliferator activated receptor- ⁇
  • CEBP- ⁇ IBMX Enhancer binding protein- ⁇
  • Their expression induces differentiation into adipocytes along with the expression of fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1), which convert saturated fatty acids to monounsaturated fatty acids when synthesized from unsaturated fatty acids to saturated fatty acids.
  • FAS fatty acid synthase
  • SCD1 stearoyl-CoA desaturase 1
  • appetite suppressants include Hutermin, Phentermine, and Lorcaserin.
  • Side effects include anxiety, dizziness, and insomnia.
  • Lipase inhibitors include Orlistat, Lorcaserin, and Marzindol. , Abdominal pain and fecal incontinence, etc.
  • An object of the present invention is to provide a food composition for the improvement or prevention of metabolic diseases comprising a blackthorn root extract as an active ingredient.
  • Another object of the present invention is to provide a food composition for weight loss containing a bramble root extract as an active ingredient.
  • Another object of the present invention is to provide a food composition for improving liver damage containing a bramble root extract as an active ingredient.
  • Another object of the present invention is to provide a food composition for suppressing appetite comprising the root extract of briar tree as an active ingredient.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating metabolic diseases comprising an extract of the root of Blackbrier as an active ingredient.
  • Another object of the present invention is to provide a method for treating metabolic diseases by administering a pharmaceutical composition containing an extract of the root of Brussels sprouts as an active ingredient to patients with metabolic diseases.
  • the food composition for improving or preventing metabolic diseases of the present invention may include an extract of the root of Blackthorn as an active ingredient.
  • the metabolic disease is obesity, metabolic syndrome, insulin deficiency, insulin-resistance related disorders, diabetes including type 2 diabetes, glucose intolerance, abnormal lipid metabolism, atherosclerosis, non-alcoholic fatty liver disease, hyperglycemia, fatty liver, dyslipidemia, It may be any one selected from the group consisting of dysfunction of the immune system associated with overweight and obesity, high cholesterol, increased triglyceride, inflammatory immune disease, and atherogenic dyslipidemia.
  • the blackthorn root extract may be extracted with water, lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
  • the lower alcohol having 1 to 4 carbon atoms may be methanol, ethanol, butanol or propanol.
  • the bramble root extract may be extracted with 20 to 80% ethanol aqueous solution.
  • the extraction temperature of the bramble root extract is 40 to 80 ° C, and the extraction time may be 3 to 10 hours.
  • the food composition for weight loss of the present invention for achieving another object described above may include a Brussels sprouts root extract as an active ingredient.
  • the food composition for improving liver damage of the present invention for achieving the above another object may include a Brussels sprouts root extract as an active ingredient.
  • the liver injury may be any one selected from the group consisting of acute alcoholic liver injury, chronic alcoholic liver injury, non-alcoholic lipid accumulation, non-alcoholic inflammation, and non-alcoholic liver injury.
  • the food composition for suppressing appetite of the present invention for achieving the above another object may include a Brussels sprouts root extract as an active ingredient.
  • the pharmaceutical composition for the prevention or treatment of metabolic diseases of the present invention for achieving another object described above may include an extract of the root of Wildflower japonica as an active ingredient.
  • a pharmaceutical composition containing a blackthorn root extract as an active ingredient may be administered to patients with metabolic diseases.
  • composition for the improvement, prevention or treatment of metabolic diseases comprising the extract of the root of the blackberry of the present invention as an active ingredient inhibits lipid accumulation, reduces the triglyceride content, increases the adrenergic receptor beta-2 content and increases the cAMP content Therefore, diseases that can be caused by obesity can be improved, prevented, or treated, and can be used as a food composition, furthermore, a health functional food or pharmaceutical composition.
  • a food composition for weight loss a food composition for improving or preventing dyslipidemia, a food composition for improving or preventing hypercholesterolemia, a food composition for improving liver damage, diabetes It can also be used as a food composition for improvement or prevention, a food composition for appetite suppression, or a pharmaceutical composition for preventing or treating metabolic diseases.
  • Figure 2a is a graph measuring the triglyceride content in cells when treated with extracts prepared according to Example 1, Example 2, and Comparative Examples 1 to 4 of the present invention.
  • Figure 2b is a graph measuring the triglyceride content in cells when treated with the extracts prepared according to Examples 1 to 6 of the present invention.
  • Figure 3 is a graph showing the energy consumption pathway of the ADRB2-cAMP pathway.
  • Figure 4 is a graph measuring the content of adrenergic receptor beta-2 in cells when treated with the extracts prepared according to Examples 1 and 2 of the present invention.
  • Figure 5 is a graph measuring the intracellular cAMP content when treated with the extracts prepared according to Examples 1 and 2 of the present invention.
  • Figure 6a is a Western blot showing the expression of PGC-1 ⁇ protein in cells when treated with extracts prepared according to Examples 1 and 2 of the present invention
  • Figure 6b is a graph quantitatively expressing the PGC-1 ⁇ protein expressed in FIG. 6a. am.
  • Figure 7a is a Western blot showing the expression of CPT-1 protein in cells when treated with extracts prepared according to Examples 1 and 2 of the present invention
  • Figure 7b is a graph quantitatively expressing the CPT-1 protein expressed in Figure 7a. am.
  • Figure 8a is a Western blot showing the expression of UCP1 protein in cells when treated with the extracts prepared according to Examples 1 and 2 of the present invention
  • Figure 8b is a graph quantitatively expressing the UCP1 protein expressed in Figure 8a.
  • Figure 9 is a graph measuring lipid accumulation in cells when treated with the extract prepared according to Example 2 of the present invention.
  • Example 10 is a graph measuring the content of PGC 1 ⁇ in cells when treated with an extract prepared according to Example 2 of the present invention.
  • Figure 11 is a graph measuring the intracellular AMPK content when treated with the extract prepared according to Example 2 of the present invention.
  • Example 12 is a graph measuring PPAR ⁇ content in cells when treated with an extract prepared according to Example 2 of the present invention.
  • Figure 13 is a graph measuring the intracellular COL1A1 content when treated with the extract prepared according to Example 2 of the present invention.
  • Figure 14 is a graph measuring the ACTA2 content in cells when treated with the extract prepared according to Example 2 of the present invention.
  • Figure 15a is a graph showing the weight gain per feed intake of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group;
  • 15B is a graph showing body weight over time in 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group;
  • 15c is a graph showing the weight gain of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group.
  • Figure 16a is a graph showing triglyceride (TG) in the blood of normal group 1, control group 1, positive control group 1, Example 1 and Example 2; 16B is a graph showing total cholesterol (t-cholesterol) in the blood of normal group 1, control group 1, positive control group 1, Example 1 and Example 2; Figure 16c is a graph showing low-density lipoprotein cholesterol (LDL-cholesterol) in the blood of 1 normal group, 1 control group, 1 positive control group, Example 1 and Example 2 groups; 16D is a graph showing high-density lipoprotein cholesterol (HDL-cholesterol) in the blood of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group.
  • TG triglyceride
  • 16B is a graph showing total cholesterol (t-cholesterol) in the blood of normal group 1, control group 1, positive control group 1, Example 1 and Example 2
  • Figure 16c is a graph showing low-density lipoprotein cholesterol (LDL-cholesterol) in the blood of 1 normal group,
  • Example 17 shows (a) AST, (b) ALT, (c) GTT, (d) ALP, and (e) LDH in the blood of normal group 1, control group 1, positive control group 1,
  • Example 1 and Example 2 is a graph showing
  • 18 is a graph showing (a) glucose, (b) insulin, (c) leptin, and (d) adiponectin in the blood of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group.
  • Example 19 is a graph showing body weight over time of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • Figure 20a is a picture taken by dual energy X-ray absorptiometry (DEXA) of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group; 20B is a graph showing the body fat mass of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • DEXA dual energy X-ray absorptiometry
  • Figure 21a is a photograph of the observation of peri-testicular adipose tissue (eWAT) of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group;
  • 21B is a graph showing the size of fat cells in normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • Figure 22a is a photograph of staining fat accumulated in liver tissue of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group; 22B is a graph showing the area of fat accumulated in the liver tissue of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • the present invention relates to a composition for the improvement, prevention or treatment of metabolic diseases, comprising an extract of the root of Blackbrier as an active ingredient.
  • the metabolic disease is obesity, metabolic syndrome, insulin deficiency, insulin-resistance related disorders, diabetes including type 2 diabetes, glucose intolerance, abnormal lipid metabolism, atherosclerosis, non-alcoholic fatty liver disease, hyperglycemia, fatty liver, dyslipidemia, It may be any one selected from the group consisting of dysfunction of the immune system associated with overweight and obesity, high cholesterol, increased triglyceride, inflammatory immune disease, and atherogenic dyslipidemia.
  • the present invention can be used as a composition for weight loss because the blackberry root extract is included as an active ingredient and suppresses the increase in weight gain;
  • a composition for improving blood flow by reducing triglyceride (TG), total cholesterol (t-cholesterol) and low-density lipoprotein cholesterol (LDL-cholesterol) content in blood and increasing the content of high-density lipoprotein cholesterol (HDL-cholesterol), dyslipidemia It can also be used as a composition for the prevention, treatment or improvement of, or a composition for the prevention, treatment or improvement of hypercholesterolemia; Since the activity of AST, ALT, GTT, ALP and LDH in the blood is excellent, it can be used as a composition for improving liver damage selected from acute alcoholic liver damage, chronic alcoholic liver damage, non-alcoholic lipid accumulation, non-alcoholic inflammation and non-alcoholic liver damage. can; Since it reduces blood sugar and increases insulin, it can also be used as a composition for preventing, treating or improving diabetes; Since it reduces leptin, it
  • composition for prevention, treatment or improvement may be a pharmaceutical composition or a food composition.
  • composition of the present invention contains the extract of the root of Brussels sprouts as an active ingredient.
  • the briar root ( Rosa multiflora root ) is good for the treatment of postpartum pain, edema, blood loss, and arthritis, and the briar mushroom parasitic on the root is the best medicine for the treatment of children's competition and epilepsy, as well as excellent efficacy in suppressing the occurrence of various cancers .
  • the root of the brier tree is used, and when other parts such as flowers, stems, and fruits of the brier tree are used, the anti-obesity effect may be reduced.
  • the bramble root is mixed with an extraction solvent in a weight ratio of 1: 5 to 25, preferably 1: 8 to 15, and mixed at 40 to 80 ° C., preferably 55 to 65 ° C. for 3 to 10 hours, preferably After extracting for 5 to 7 hours, concentration under reduced pressure is performed to prepare an extract.
  • concentration under reduced pressure is performed to prepare an extract.
  • the active ingredient of the root of brier may be extracted in a small amount, and the effect of improving, preventing or treating obesity may be reduced.
  • the extraction solvent for extracting each extract is water, lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
  • the lower alcohol include 20 to 80% methanol, ethanol, butanol or propanol.
  • an extract extracted with 20 to 80% aqueous ethanol solution preferably acts to improve, prevent or treat obesity.
  • extract' refers to extracts obtained by extracting components contained in the roots of Biloba using the above solvent, fractions fractionated therefrom, concentrates obtained by additionally concentrating these extracts or fractions, and purified or separated purified products thereof. Including, it is used in the sense of including the extract, fraction, concentrate or purified product dried or pulverized powder thereof.
  • the purified product For the preparation of the purified product, a variety of additionally carried out, such as passing through an ultrafiltration membrane having a molecular weight cut-off value, or separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity). A purification method may be added.
  • the present invention relates to a food composition for preventing or alleviating obesity, comprising an extract of the root of Biloba japonica as an active ingredient.
  • the 'food composition' is a food ingredient that can be used as a food described in the food standards and specifications ('Food Code') commonly used in food manufacturing, in addition to the extract of the root of Biloba as an active ingredient, and food additives described in the Food Additive Code include
  • the carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sugar, lactose and the like; oligosaccharides or polysaccharides such as dextrin, starch syrup, cyclodextrin and the like; Sugar alcohols such as xylitol, sorbitol, erythritol and the like can be used.
  • flavoring agent natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used.
  • natural flavoring agents thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the Brussels sprouts root extract does not need to be particularly limited as long as the content can prevent or treat obesity diseases, but, for example, 0.1 to 99% by weight, 0.5 to 95% % by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, may be included in 5 to 50% by weight.
  • the active ingredient, briar root extract varies depending on the condition, body weight, presence or absence or degree and period of disease of the eater, but may be appropriately selected by a person skilled in the art.
  • it may be 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, still more preferably 20 to 800 mg, and most preferably 50 to 500 mg based on the daily dose.
  • the number of administrations need not be particularly limited, but can be adjusted by a person skilled in the art within the range of three times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or health control, it may be less than the above range.
  • the food composition does not need to be particularly limited, but may be, for example, a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation or beverage formulation.
  • the bramble root extract can be added, and the food that can be added does not need to be particularly limited, but for example, food standards according to Article 7 of the Food Sanitation Act and confectionery, bread or rice cakes, processed cocoa products or chocolates, processed meat or egg products, processed fish meat products, tofu or jelly, noodles, teas, coffee, beverages, special purpose foods, pastes, It can be added to seasoning foods, dressings, kimchi, salted fish, pickled foods, stewed foods, alcoholic beverages, raisins, and other foods. In addition, it can be added to dairy products, processed meat products, packaged meat, and egg products exemplified in the processing standards and ingredient specifications of livestock products ('livestock product code') according to Article 4 of the Livestock Products Sanitation Control Act.
  • livestock products 'livestock product code'
  • the food composition containing the bramble root extract as an active ingredient can be used alone as a “health functional food for preventing or improving obesity”.
  • the above ‘functional health food’ refers to food manufactured (including processing) in accordance with legal standards using raw materials or ingredients that have functional properties useful for the human body (Article 3, Subparagraph 1 of the Health Functional Food Act).
  • the term 'health functional food' may differ in terminology or scope from country to country, but 'Dietary Supplement' in the US, 'Food Supplement' in Europe, 'Health Functional Food' or 'Health Functional Food' in Japan. It may correspond to 'Food for Special Health Use (FoSHU)' or 'Health Food' in China.
  • the food composition or health functional food may additionally contain food additives, and the suitability as a food additive is determined according to the standards and standards for the item in accordance with the general rules and general test methods of the 'Food Additive Code' unless otherwise specified. follow
  • the health functional food is a raw material notified as a 'functional raw material' used for "improvement of neutral fat in the blood" or individually recognized raw material, together with the bramble root extract, univex bamboo leaf extract, sardine fish oil, DHA concentrated oil , Indigestible maltodextrin, vegetable oil diglyceride, refined squid oil, globin hydrolyzate, etc.
  • Raw materials notified as 'functional raw materials' used for "improvement of blood cholesterol” or individually recognized raw materials such as aloe extract, aloe complex extract, bamboo leaf extract, spirulina, sugarcane wax alcohol, linseed, puer tea extract, Health functional food ingredients related to blood cholesterol improvement, such as red yeast rice, barley beta-glucan extract, Changnyeong onion extract, green tea extract, and red grape fermented concentrate, are used in combination;
  • Raw materials notified as 'functional raw materials' used for "body fat reduction” or individually recognized raw materials Lactobacillus gasseri BNR17, L-carnitine tartrate, Garcinia cambogia peel extract, conjugated linolenic acid (free fatty acid), conjugated linolenic acid (triglyceride) , green mate extract, green coffee bean extract, sesame leaf extract, green tea extract, soybean embryo extract, etc.
  • the present invention provides a method for treating obesity by administering the composition to humans or non-human animals.
  • the present invention provides a novel use of the extract of the root of the blackthorn tree for the preparation of a medicine for preventing or treating obesity, or a medicine for animals.
  • the 'pharmaceutical composition' or 'medicine' may further include appropriate carriers, excipients, and diluents commonly used in the manufacture of pharmaceutical compositions, etc., in addition to the Brussels sprouts root extract as an active ingredient.
  • the 'carrier' is a compound that facilitates the addition of the compound into cells or tissues.
  • the 'diluent' is a compound diluted in water that not only stabilizes the biologically active form of the target compound, but also dissolves the compound.
  • the carrier, excipient, and diluent are not particularly limited, but, for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • the amount of the pharmaceutical composition, drug, veterinary pharmaceutical composition, or veterinary drug used may vary depending on the age, sex, and weight of the patient or animal to be treated, and above all, the condition of the subject to be treated, a specific category of disease to be treated, or It will depend on the type, route of administration, and nature of the therapeutic used.
  • the pharmaceutical composition, drug, veterinary pharmaceutical composition or veterinary drug is appropriately selected according to the absorption rate of the active ingredient in the body, the rate of excretion, the age and weight, sex and condition of the patient or animal to be treated, the severity of the disease to be treated, etc. , It is generally preferred to administer 0.1 to 1,000 mg/kg, preferably 1 to 500 mg/kg, more preferably 5 to 250 mg/kg, and most preferably 10 to 100 mg/kg per day.
  • the unit dosage formulation thus formulated can be administered several times at regular time intervals as needed.
  • the pharmaceutical composition, medicament, veterinary pharmaceutical composition, or veterinary medicament may be administered individually as a prophylactic or therapeutic agent, or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.
  • the pharmaceutical composition, drug, veterinary pharmaceutical composition, or veterinary drug may be formulated into oral dosage forms such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc. according to conventional methods and used. there is. When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, etc., and these solid preparations contain at least one excipient such as starch, calcium carbonate, sugar or lactose, and gelatin in the compound. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. .
  • the treatment method of the metabolic disease is to administer the composition to humans or non-human animals, particularly mammals, for example, to administer the composition to a subject to be treated who is a metabolic disease patient.
  • the dosage, administration method and number of administrations for the treatment may refer to the dosage, administration method and number of administrations of the pharmaceutical composition, medicine, veterinary pharmaceutical composition or veterinary medicine.
  • the pharmaceutical composition for preventing or treating metabolic diseases of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, or biological response modifiers.
  • Example 1 50% aqueous ethanol solution
  • Brier briar root and 50% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 5 hours to obtain a briar root extract (yield: 7.30%).
  • Brier briar root and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 5 hours to obtain a briar root extract (yield: 7.11%).
  • Brier briar root and 50% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 3 hours to obtain a briar root extract.
  • Brier briar root and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 3 hours to obtain a briar root extract.
  • Brier briar root and 50% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 7 hours to obtain a briar root extract.
  • Brier briar root and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 7 hours to obtain a briar root extract.
  • Brier stem and 50% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 5 hours to obtain an extract from Brier stem.
  • Brier stem and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 5 hours to obtain an extract from Brier stem.
  • Brier berries and 50% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 5 hours to obtain an extract of Brussels sprouts.
  • Brier berries and 70% ethanol aqueous solution were mixed at a weight ratio of 1:10 and extracted at 60° C. for 5 hours to obtain a briar fruit extract.
  • 3T3-L1 preadipocytes were purchased from an american type culture collection (ATCC, Manassas, USA) and supplemented with 10% bovine calf serum (Welgene, Daegu, Korea) and 1% penicillin-streptomycin (Welgene, Daegu, Korea) dulbecco's. They were cultured in modified eagle's medium (DMEM, Welgene, Daegu, Korea) medium at 37 °C and 5% CO 2 conditions.
  • DMEM modified eagle's medium
  • 3T3-L1 pre-adipocytes into adipocytes 5X10 5 cells/well of cells were dispensed into a 6 well plate, the cells were completely densely cultured, the medium was exchanged, and the culture was further cultured for 2 days. Differentiation was initiated by culturing for 2 days in DMEM medium containing MDI solution (0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.5 uM dexamethasone, 10 ug/mL insulin) and 10% FBS. Differentiation was performed for 2 days by replacing the medium with DMEM medium containing ml insulin and 10% FBS.
  • MDI solution 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.5 uM dexamethasone, 10 ug/mL insulin
  • Example 1 and Example 2 were simultaneously treated at concentrations of 0.05, 0.1, and 0.2 mg/mL, respectively, each time the medium was exchanged, and cultured until differentiation induction was completed.
  • the differentiated cells were washed twice with PBS, treated with 10% formalin, fixed at 4 ° C for 1 hour, washed, and treated with 60% isopropanol solution to stain adipocytes.
  • the stained cells were washed with PBS, oil red O was eluted with 100% isopropanol, and the absorbance at 520 nm was measured and lipid accumulation was confirmed by comparison with the control group.
  • Intracellular triglyceride contents were measured using EZ-Triglyceride Quantification Assay Kit.
  • 5X10 5 cells/well of cells were dispensed into a 6 well plate, the cells were completely densely cultured, the medium was exchanged, and the culture was further cultured for 2 days. Differentiation was initiated by culturing for 2 days in DMEM medium containing MDI solution (0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.5 uM dexamethasone, 10 ug/mL insulin) and 10% FBS.
  • MDI solution 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.5 uM dexamethasone, 10 ug/mL insulin
  • Differentiation was performed for 2 days by replacing the medium with DMEM medium containing ml insulin and 10% FBS. After that, by culturing for 4 days in DMEM medium containing only 10% FBS, differentiation into adipocytes forming fat droplets by intracellular fat accumulation was completed.
  • the MDI solution and the extracts of Example 1 and Example 2 were simultaneously treated at concentrations of 0.05, 0.1, and 0.2 mg/mL, respectively, each time the medium was exchanged, and cultured until differentiation induction was completed.
  • the differentiated cells were washed twice with PBS, homogenized using NP40, heated at 100° C. to dissolve intracellular triglycerol, and centrifuged at 13,000 rpm for 2 minutes to remove insoluble substances.
  • Figure 2a is a graph measuring the triglyceride content in cells when treated with extracts prepared according to Example 1, Example 2, and Comparative Examples 1 to 4 of the present invention.
  • Figure 2b is a graph measuring the triglyceride content in cells when treated with the extracts prepared according to Examples 1 to 6 of the present invention.
  • Intracellular Adrenergic receptor beta 2 measurement was analyzed using a mouse beta-2 adrenergic receptor ELISA kit.
  • Differentiated 3T3-L1 adipocytes were treated with the extracts of Example 1 and Example 2 at concentrations of 0.05, 0.1, and 0.2 mg/mL, respectively, and cultured for 24 hours, followed by recovery of the medium and centrifugation at 3,000 rpm for 10 minutes. used in After dispensing 100 uL of the culture medium into a 96 well plate and reacting at 37 ° C for 90 minutes, 100 uL of biotin-detection antibody working solution was added.
  • Figure 4 is a graph measuring the content of adrenergic receptor beta-2 in cells when treated with the extracts prepared according to Examples 1 and 2 of the present invention.
  • Example 1 exhibited 124.7%, 142.1%, and 130.5% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL; It was confirmed that the extract of Example 2 exhibited 135.4%, 115.5%, and 134.1% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL, respectively.
  • 845 uL 1X assay buffer was mixed to prepare a sample to be used in the experiment. Add 50 uL sample, standard, and 10 uL reconstituted cAMP antibody to the Protein G coated 96-well plate and react while stirring at room temperature for 1 hour. Reacted while stirring at room temperature. After 1 hour, washing 5 times with 200 uL 1X assay buffer, adding 100 uL HRP developer and reacting while stirring at room temperature for 1 hour. To terminate the reaction, 100 uL 1 M HCl was added and absorbance was measured at 450 nm.
  • Figure 5 is a graph measuring the intracellular cAMP content when treated with the extracts prepared according to Examples 1 and 2 of the present invention.
  • Example 1 exhibited 128.5%, 107.3%, and 107.1% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL, respectively; It was confirmed that the extract of Example 2 exhibited 131.2%, 140.9%, and 143.2% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL, respectively.
  • Differentiated 3T3-L1 adipocytes were treated with the extracts of Examples 1 and 2 at concentrations of 0.05, 0.1, and 0.2 mg/mL, respectively, and cultured for 24 hours.
  • the cultured cells were scraped with a cell scraper, centrifuged at 5,000 rpm for 10 minutes, and then lysed using RIPA buffer.
  • the same amount of protein quantified by the bradford method was mixed in a sample buffer containing sodium dodecyl sulfate (SDS) and ⁇ -mercapto-ethanol at a ratio of 3:1 and heated at 100 °C for 10 minutes.
  • SDS sodium dodecyl sulfate
  • Protein samples were electrophoresed by SDS-PAGE and then transferred to a polyvinylidene fluoride membrane (0.45 ⁇ m, PVDF transfer membrane, Thermo, Rockford, IL, USA). Membrane was blocked for 2 hours in tris-buffered saline (TBS) containing 0.1% tween 20 and 5% skim milk. After that, PGC-1 ⁇ (1:1000), CPT-1 (1:1000), UCP-1 (1:1000), and ⁇ -actin (1:5000) were reacted overnight in a buffer to which primary antibodies were added. It was washed three times for 5 minutes each with TBS-T (TBS containing 0.1% tween 20).
  • TBS-T TBS containing 0.1% tween 20
  • Figure 6a is a Western blot showing the expression of PGC-1 ⁇ protein in cells when treated with extracts prepared according to Examples 1 and 2 of the present invention
  • Figure 6b is a graph quantitatively expressing the expressed PGC-1 ⁇ protein.
  • Example 1 exhibited 116.4%, 131.1%, and 149.6% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL;
  • Example 2 When treated with the extract of Example 2 at 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL, respectively, 125.8% and 136.7%. It was confirmed that it represents 144.6%.
  • CPT-1 Carnitine palmitoyltransferase 1
  • Figure 7a is a Western blot showing the expression of CPT-1 protein in cells when treated with extracts prepared according to Examples 1 and 2 of the present invention
  • Figure 7b is a graph quantitatively expressing the expressed CPT-1 protein.
  • the control in Fig. 7b is adipocyte.
  • Example 1 exhibited 114.1%, 123.6%, and 131.4% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL; It was confirmed that the extract of Example 2 exhibited 134.3%, 138.1%, and 139.7% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL, respectively.
  • Figure 8a is a Western blot showing the expression of UCP1 protein in cells upon treatment with the extracts prepared according to Examples 1 and 2 of the present invention
  • Figure 8b is a graph quantitatively expressing the expressed UCP1 protein.
  • Example 1 exhibited 148.3%, 137.2%, and 131.9% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL; It was confirmed that the extract of Example 2 exhibited 140.3%, 128.2%, and 124.8% when treated with 0.05 mg/mL, 0.1 mg/mL, and 0.2 mg/mL, respectively.
  • HepG2 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) supplemented with 10% heat inactivated Fetal Bovine Serum (Gibco, Life Technologies, Grand Island, NY, USA) and 1% penicillin-streptomycin (P/S, Gibco). 37 °C, 5% CO 2 It was cultured under conditions.
  • DMEM Dulbecco's Modified Eagle's Medium
  • P/S penicillin-streptomycin
  • HepG2 cells were cultured overnight at 5x10 5 cells/well in a 12 Well Plate, exchanged with DMEM Media containing FFA-free bovine serum albumin, and then 250 uM Palmitic acid and the extract of Example 2 were mixed with 0, 12.5, 25, 50, and 100 ug/ml concentrations were simultaneously treated and the cells were cultured for 24 hours. After the end of the culture, the cells were washed with DPBS twice or more and treated with 4% PFA (paraformaldehyde) solution for 30 minutes to fix the cells. The fixed cells were washed two or more times, reacted with 60% isopropanol for 5 minutes, and then stained the lipids accumulated in the cells using Oil Red O staining solution. The stained cells were washed two or more times, 100% isopropanol was used to elute the stained ORO cells, and then transferred to a 96-well plate, and the absorbance at 510 nm was measured to confirm lipid accumulation.
  • DPBS twice or more and
  • Figure 9 is a graph measuring lipid accumulation in cells when treated with the extract prepared according to Example 2 of the present invention.
  • HepG2 cells were cultured overnight at 1x10 6 cells/well in a 6-Well Plate, and the cells were cultured for 24 hours by simultaneously treating palmitic acid and the extract of Example 2.
  • the cultured cells were washed with DPBS, and the cells were pulverized using the lysis buffer included in the RNeasy mini kit (Qiagen, Hilden, Germany), and the RNA in the cells was isolated using an RNeasy spin column.
  • the concentration of the isolated RNA was measured using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and reacted at 50 °C for 60 minutes using the TOPscriptTM RT DryMIX kit (Enzynomics, Daejeon, Korea), and at 95 °C.
  • qPCR was performed using SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). mRNA was detected using a Biorad CFX96 real-time PCR detection system and gene expression was analyzed using the ⁇ CT calculation method.
  • Example 10 is a graph measuring the PGC 1 ⁇ content in cells when treated with an extract prepared according to Example 2 of the present invention.
  • PGC 1 ⁇ is a thermogenic indicator, and when its expression increases, fat in the tissue is consumed as heat, resulting in a decrease in body fat. (vehicle control), it was confirmed that PGC1 ⁇ gene expression increased by 0.95 and 1.41 times, respectively.
  • Figure 11 is a graph measuring the intracellular AMPK content when treated with the extract prepared according to Example 2 of the present invention.
  • Example 12 is a graph measuring PPAR ⁇ content in cells when treated with an extract prepared according to Example 2 of the present invention.
  • PPAR ⁇ is a gene that promotes the catabolism of fat and promotes the oxidation of fatty acids through UCP in adipose tissue and muscle.
  • PPAR ⁇ gene increased 1.23-fold and 1.51-fold, respectively, compared to the control group (vehicle control).
  • Figure 13 is a graph measuring the intracellular COL1A1 content when treated with the extract prepared according to Example 2 of the present invention.
  • COL1A1 is a liver fibrosis-related gene.
  • Figure 14 is a graph measuring the ACTA2 content in cells when treated with the extract prepared according to Example 2 of the present invention.
  • the ACTA2 ( ⁇ -SMA) gene is highly expressed in the Liver injury model, and is known to be rarely expressed in normal conditions, and the expression of the gene increased to 1.3 when treated with palmitic acid (PA). After treatment with the extract of Example 2, it was confirmed that it decreased to 0.4.
  • a 4-week-old SD rat male (130-150 g) was distributed and used for experiments after adaptation for 1 week under conditions of temperature 22 ⁇ 1 °C, humidity 55 ⁇ 3%, and light-dark cycle of 12 hours (8 am/pm).
  • normal group 1 normal was fed a formulated feed (AIN-76A) and control group 1 was fed a high-fat (fat 60%) feed to induce obesity and use it for testing.
  • the rest of the group was orally administered the control substance and the extracts of Examples 1 and 2 while feeding a high-fat diet.
  • the blood of the experimental animals was collected and analyzed using an automated chemistry analyzer (Thermo, Thermo).
  • Normal group 1 normal diet + CMC (sodium carboxymethyl cellulose) administration
  • Positive control 1 high fat diet + Garcinia cambogia 200 mg/kg
  • Example 1 high fat diet + 100 mg/kg of extract of Example 1
  • Example 2 high fat diet + 100 mg/kg of the extract of Example 2
  • the extracts and Garcinia cambogia of Examples 1 and 2 were diluted in CMC and used.
  • Figure 15a is a graph showing the weight gain per feed intake of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group;
  • 15B is a graph showing body weight over time in 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group;
  • 15c is a graph showing the weight gain of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group.
  • Figure 16a is a graph showing triglyceride (TG) in the blood of normal group 1, control group 1, positive control group 1, Example 1 and Example 2; 16B is a graph showing total cholesterol (t-cholesterol) in the blood of normal group 1, control group 1, positive control group 1, Example 1 and Example 2; Figure 16c is a graph showing low-density lipoprotein cholesterol (LDL-cholesterol) in the blood of 1 normal group, 1 control group, 1 positive control group, Example 1 and Example 2 groups; 16D is a graph showing high-density lipoprotein cholesterol (HDL-cholesterol) in the blood of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group.
  • TG triglyceride
  • 16B is a graph showing total cholesterol (t-cholesterol) in the blood of normal group 1, control group 1, positive control group 1, Example 1 and Example 2
  • Figure 16c is a graph showing low-density lipoprotein cholesterol (LDL-cholesterol) in the blood of 1 normal group,
  • the group ingesting the extracts of Examples 1 and 2 had blood triglyceride (TG), total cholesterol (t-cholesterol) and low-density lipoprotein cholesterol (LDL-cholesterol) compared to the control group. cholesterol) was reduced, and it was confirmed that the content of high-density lipoprotein cholesterol (HDL-cholesterol) increased.
  • TG blood triglyceride
  • t-cholesterol total cholesterol
  • LDL-cholesterol low-density lipoprotein cholesterol
  • the extracts of Examples 1 and 2 reduce the contents of triglyceride (TG), total cholesterol (t-cholesterol) and low-density lipoprotein cholesterol (LDL-cholesterol) in the blood, and the content of high-density lipoprotein cholesterol (HDL-cholesterol) Because it increases the blood flow improvement health functional food composition; a composition for preventing, treating or improving dyslipidemia; Alternatively, it can be used as a composition for preventing, treating or improving hypercholesterolemia.
  • the composition for prevention, treatment or improvement may be a pharmaceutical composition or a food composition.
  • Example 17 shows (a) AST, (b) ALT, (c) GTT, (d) ALP, and (e) LDH in the blood of normal group 1, control group 1, positive control group 1,
  • Example 1 and Example 2 is a graph showing
  • the group ingesting the extracts of Examples 1 and 2 showed AST, ALT, GTT, ALP, and LDH similar to those of the normal group 1, so it was confirmed that hepatotoxicity was not observed.
  • the extracts of Examples 1 and 2 have excellent activities of AST, ALT, GTT, ALP and LDH in the blood, they are selected from among acute alcoholic liver damage, chronic alcoholic liver damage, non-alcoholic lipid accumulation, non-alcoholic inflammation and non-alcoholic liver damage. It can be used as any one food or pharmaceutical composition for improving liver damage.
  • 18 is a graph showing (a) glucose, (b) insulin, (c) leptin, and (d) adiponectin in the blood of 1 normal group, 1 control group, 1 positive control group, Example 1 group, and Example 2 group.
  • the extracts of Examples 1 and 2 reduce blood sugar and increase insulin, they can also be used as a composition for preventing, treating or improving diabetes; Since it reduces leptin, it can also be used as a food composition for appetite suppression.
  • the composition for prevention, treatment or improvement may be a pharmaceutical composition or a food composition.
  • C57BL6J mice 6-week-old males were received from Coretech and used for experiments after adaptation for one week under conditions of temperature of 22 ⁇ 1 °C, humidity of 55 ⁇ 3%, and light/dark cycle of 12 hours (8 am/pm).
  • the normal group 2 normal was fed a normal feed (Orient)
  • the control group 2 was fed a high-fat (fat 60%, Research diet. D16042106) feed to induce obesity and use the test.
  • the rest of the group was orally administered the control substance and the extract of Example 2 while feeding a high-fat diet.
  • Normal group 2 normal diet + distilled water
  • Control group 2 high fat diet + distilled water
  • Positive control 2 high fat diet + Garcinia cambogia 400 mg/kg
  • Positive control 3 high fat diet + Cissus antarctica 65 mg/kg
  • Example 2 high fat diet + 150 mg/kg extract of Example 2
  • Example 19 is a graph showing body weight over time of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • Test Example 17 Body fat measurement using DEXA
  • body fat was measured using dual energy X-ray absorptiometry (DEXA) before organ extraction. Radiographs of body fat were displayed in three modes according to low-density fat (blue), medium-density fat (yellow), and high-density fat (red).
  • Figure 20a is a picture taken by dual energy X-ray absorptiometry (DEXA) of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group; 20B is a graph showing the body fat mass of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • DEXA dual energy X-ray absorptiometry
  • Example 2 (200) group, and Example 2 (150) group have a large number of body cavity and subcutaneous fat This accumulation was confirmed (red color).
  • Example 2 (200) group had a significant decrease in body fat compared to other groups except for the normal group 2.
  • peri-testicular adipose tissue eWAT
  • the eWAT was fixed with 10% formalin solution, embedded in paraffin, and sectioned. After staining with hematoxylin and eosin, the stained tissue was observed and photographed using an optical microscope (Olympus, Japan). Adipocyte size was then measured using ImageJ software (National Institutes of Health, Bethesda, MD).
  • Figure 21a is a photograph of the observation of peri-testicular adipose tissue (eWAT) of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group;
  • 21B is a graph showing the size of fat cells in normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • the size of adipocytes increased by about 2 times compared to normal group 2 due to fat accumulation in the control group 2 with a high-fat diet, Example 2 (200) group, positive control group 2 and the positive control group 3 confirmed that the size of adipocytes was significantly reduced.
  • Liver tissue excised at autopsy was fixed using 10% formalin, embedded in OCT compound, and then frozen sections were prepared. Thereafter, after sufficiently staining the fat components accumulated in the cells with a previously prepared Oil red o solution, they were observed and photographed using an optical microscope (Olympus, Japan). The area (%) of lipid vesicles stained with Oil Red O was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD).
  • Figure 22a is a photograph of staining fat accumulated in liver tissue of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group; 22B is a graph showing the area of fat accumulated in the liver tissue of normal group 2, control group 2, positive control group 2, positive control group 3, Example 2 (200) group, and Example 2 (150) group.
  • Example 22a and 22b in the control group 2, fat was accumulated in the liver tissue on a high-fat diet, and a large number of stained fat vesicles were observed compared to the normal group 2, Example 2 (200) group, In Example 2 (150) group, positive control group 2 and positive control group 3, it was confirmed that the area of fat accumulated in the liver tissue was significantly reduced.
  • a powder is prepared by mixing the above ingredients and filling them in an airtight bag.
  • tablets are prepared by tableting according to a conventional tablet manufacturing method.
  • Capsules are prepared by mixing the above ingredients and filling them into gelatin capsules according to a conventional capsule preparation method.
  • each component is dissolved in purified water, lemon flavor is added in an appropriate amount, the above components are mixed, and then purified water is added to adjust the total amount to 100g, and then filled into a brown bottle to be sterilized. to prepare a liquid.
  • Vitamin A Acetate 70 ⁇ g
  • Vitamin B6 0.5 mg
  • Vitamin B12 0.2 ⁇ g
  • composition ratio of the above vitamin and mineral mixture was prepared by mixing ingredients suitable for granules in a preferred embodiment, the mixing ratio may be arbitrarily modified, and after mixing the above ingredients according to a conventional granule manufacturing method, It can be prepared and used for preparing a health functional food composition according to a conventional method.
  • the resulting solution is filtered and collected in a sterilized 2 L container, sealed and sterilized, and then refrigerated. It is used for preparing the functional beverage composition of the present invention.
  • composition ratio is a mixture of ingredients suitable for a relatively favorite beverage in a preferred embodiment
  • the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the class of demand, the country of demand, and the purpose of use.
  • the composition comprising the blackberry root extract of the present invention as an active ingredient is a food composition for weight loss, a food composition for improving or preventing dyslipidemia, a food composition for improving or preventing hypercholesterolemia, a food composition for improving liver damage, It can be used as a food composition for improving or preventing diabetes, a food composition for suppressing appetite, or a pharmaceutical composition for preventing or treating metabolic diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour soulager, prévenir ou traiter l'obésité et les maladies métaboliques. Plus précisément, la composition contient un extrait de racine de bruyère en tant que principe actif, et en tant que telle, peut soulager, prévenir ou traiter des maladies provoquées par l'obésité et des maladies métaboliques et peut être utilisée en tant que composition alimentaire et, en outre, en tant qu'aliment fonctionnel de santé ou composition pharmaceutique.
PCT/KR2022/021566 2021-12-29 2022-12-29 Composition contenant un extrait de racine de bruyère pour le soulagement, la prévention ou le traitement de l'obésité et de maladies métaboliques WO2023128636A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2021-0191073 2021-12-29
KR20210191073 2021-12-29
KR1020220187409A KR20230101740A (ko) 2021-12-29 2022-12-28 찔레나무 뿌리 추출물을 포함하는 비만 및 대사질환의 개선, 예방 또는 치료용 조성물
KR10-2022-0187409 2022-12-28

Publications (1)

Publication Number Publication Date
WO2023128636A1 true WO2023128636A1 (fr) 2023-07-06

Family

ID=86999671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/021566 WO2023128636A1 (fr) 2021-12-29 2022-12-29 Composition contenant un extrait de racine de bruyère pour le soulagement, la prévention ou le traitement de l'obésité et de maladies métaboliques

Country Status (1)

Country Link
WO (1) WO2023128636A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070068837A (ko) * 2005-12-27 2007-07-02 일동제약주식회사 영실로부터 얻은 지방세포분화 억제용 활성 분획 조성물
US20150118266A1 (en) * 2012-05-29 2015-04-30 Korea Food Research Institute Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredients
KR20190023962A (ko) * 2017-08-30 2019-03-08 한국식품연구원 찔레열매 추출물의 분획물을 유효성분으로 포함하는 면역 질환의 예방, 개선 또는 치료용 조성물
KR102309913B1 (ko) * 2019-11-27 2021-10-06 한국한의약진흥원 영실근 추출물을 함유하는 숙취해소 및 알코올성 간손상 개선용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070068837A (ko) * 2005-12-27 2007-07-02 일동제약주식회사 영실로부터 얻은 지방세포분화 억제용 활성 분획 조성물
US20150118266A1 (en) * 2012-05-29 2015-04-30 Korea Food Research Institute Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredients
KR20190023962A (ko) * 2017-08-30 2019-03-08 한국식품연구원 찔레열매 추출물의 분획물을 유효성분으로 포함하는 면역 질환의 예방, 개선 또는 치료용 조성물
KR102309913B1 (ko) * 2019-11-27 2021-10-06 한국한의약진흥원 영실근 추출물을 함유하는 숙취해소 및 알코올성 간손상 개선용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI YONG-SOON, HAE-IK RHEE, KWEON-JUNG YONG, SEUNG-SHI HAM, SANG-YOUNG LEE: "Cholesterol-Lowering Effects of Extracts of Rosa multiflora Roots in Chickens.", KOREAN JOURNAL OF LIPIDOLOGY, vol. 3, no. 2, 1 January 1993 (1993-01-01), pages 215 - 220, XP093075204 *

Similar Documents

Publication Publication Date Title
WO2018124508A1 (fr) Composition pour la prévention et le traitement de maladies musculaires ou pour l'amélioration de la fonction musculaire, contenant de l'acide 3,5-dicaféoylquinique ou de l'extrait de chrysanthème
WO2014104672A1 (fr) Extrait purifié isolé à partir de pseudolysimachion rotundum var subintegrum contenant une grande quantité de principe actif, sa préparation et composition le comprenant comme principe actif pour prévenir une inflammation, une allergie et l'asthme
WO2021137678A1 (fr) Composition contenant des extraits de mûrier à papier
WO2018062777A1 (fr) Composition d'amélioration de la force musculaire et de la masse musculaire comprenant un peptide de jus de soja dérivé de soja germé traité avec de l'eau de tangerine non mûre
WO2020071667A1 (fr) Composition comprenant un extrait de corète potagère en tant que principe actif permettant d'améliorer le microbiome intestinal ou de soulager, de prévenir ou de traiter une inflammation intestinale, une hyperperméabilité intestinale, l'obésité ou une maladie métabolique
WO2012067316A1 (fr) Composition pour la prévention ou le traitement de maladies métaboliques ou de complications de celles-ci contenant des composés à base de ptérocarpane ou des sels pharmaceutiquement acceptables de ceux-ci comme principe actif ou composition anti-oxydation
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2010090498A2 (fr) Composition pharmaceutique et composition d'aliment naturel contenant un extrait de youngia denticulata, une fraction de celui-ci, ou un composé isolé à partir de celui-ci en tant que substance active pour améliorer la fonction hépatique
WO2023128636A1 (fr) Composition contenant un extrait de racine de bruyère pour le soulagement, la prévention ou le traitement de l'obésité et de maladies métaboliques
WO2010041908A2 (fr) Nouvelle utilisation d'un dérivé de panduratine ou d'un extrait de boesenbergia pandurata
WO2013069934A1 (fr) Composition pour traiter et prévenir l'obésité, contenant de l'extrait d'agropyre comme principe actif
WO2015002430A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'asthme comprenant un extrait de pistacia weinmannifolia j. poiss. ex franch ou une fraction de celui-ci
WO2012081831A2 (fr) Composition comprenant un extrait de loranthus yadoriki sieb. ayant une activité inhibitrice sur la monoamine oxydase
WO2018221922A1 (fr) Composition pour la prévention et le traitement de maladies musculaires, contenant un extrait de coptidis rhizoma, et son utilisation
WO2012138146A9 (fr) Composition contenant de la poudre ou un extrait traité(e) thermiquement de glycine soja en tant qu'ingrédient actif destiné à la prévention et au traitement du diabète sucré et des complications du diabète
WO2010090423A2 (fr) Composition comprenant un extrait de substance médicamenteuse brute combinée pour la prévention et le traitement d'hyperlipidémie et d'hyperlipidémie diabétique
WO2010143825A2 (fr) Agent antiarthritique à l'aide de cyathula officinalis
WO2016190689A2 (fr) Composition permettant de prévenir, de soulager ou de traiter les maladies musculaires ou d'améliorer la fonction musculaire
WO2020145619A1 (fr) Composition pour la prévention des allergies, le soulagement de la dermatite atopique ou la régénération de la peau, contenant, en tant que principe actif, un undécane ou un undécanal
WO2015046743A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies thyroïdiennes, contenant de l'extrait de fruit de lonicera caerulea l. var. edulis comme principe actif
WO2019198982A1 (fr) Composition pour prévenir ou améliorer l'atrophie musculaire squelettique contenant de la kukoamine a et de la kukoamine b en tant que principes actifs
WO2019172566A1 (fr) Agent anti-stress, composition d'agent anti-anxiété ou antidépresseur contenant de l'ionone en tant que principe actif
WO2022071692A1 (fr) Composition comprenan de l'extrait de feuille d'hippophae rhamnoides en tant que principe actif pour soulager, prévenir ou traiter une complication du diabète sucré
WO2017192013A1 (fr) Composition pour améliorer la fonction musculaire ou pour améliorer les performances d'exercice, comprenant du vigna angularis var. angularis
WO2024090929A1 (fr) Composition pour inhiber l'accumulation de graisse, contenant un germe de graine de cassia et une pousse de sarrasin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22916777

Country of ref document: EP

Kind code of ref document: A1